INSM Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of 0.91%. Insmed, Inc.'s return on equity of -192.35% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.

Insmed, Inc. has a consensus price target of $214.32, signalling upside risk potential of 31.94%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.42%. Given that Insmed, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Insmed, Inc. is more attractive than Amicus Therapeutics, Inc..

Insmed, Inc. has a beta of 1.100, which suggesting that the stock is 10.036% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.483, suggesting its less volatile than the S&P 500 by 51.684%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $263.8M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Insmed, Inc.'s net income of -$328.5M is lower than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 52.50x versus 7.06x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of -18.24%. Insmed, Inc.'s return on equity of -192.35% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53%.

Insmed, Inc. has a consensus price target of $214.32, signalling upside risk potential of 31.94%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $668.57 which suggests that it could grow by 22.25%. Given that Insmed, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Insmed, Inc. has a beta of 1.100, which suggesting that the stock is 10.036% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -0.995, suggesting its less volatile than the S&P 500 by 199.535%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $263.8M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $321.1M. Insmed, Inc.'s net income of -$328.5M is lower than Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 52.50x versus 13.20x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics, Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of -81.96%. Insmed, Inc.'s return on equity of -192.35% beat PTC Therapeutics, Inc.'s return on equity of --.

Insmed, Inc. has a consensus price target of $214.32, signalling upside risk potential of 31.94%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $86.50 which suggests that it could grow by 27.64%. Given that Insmed, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Insmed, Inc. is more attractive than PTC Therapeutics, Inc..

Insmed, Inc. has a beta of 1.100, which suggesting that the stock is 10.036% more volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.555, suggesting its less volatile than the S&P 500 by 44.489%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $263.8M, which are larger than PTC Therapeutics, Inc. quarterly revenues of $164.7M. Insmed, Inc.'s net income of -$328.5M is lower than PTC Therapeutics, Inc.'s net income of -$135M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while PTC Therapeutics, Inc.'s PE ratio is 8.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 52.50x versus 3.21x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines, Inc. has a net margin of -124.5% compared to Insmed, Inc.'s net margin of --. Insmed, Inc.'s return on equity of -192.35% beat Revolution Medicines, Inc.'s return on equity of -59.94%.

Insmed, Inc. has a consensus price target of $214.32, signalling upside risk potential of 31.94%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $133.70 which suggests that it could grow by 34.89%. Given that Revolution Medicines, Inc. has higher upside potential than Insmed, Inc., analysts believe Revolution Medicines, Inc. is more attractive than Insmed, Inc..

Insmed, Inc. has a beta of 1.100, which suggesting that the stock is 10.036% more volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 1.011, suggesting its more volatile than the S&P 500 by 1.093%.

Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend.

Insmed, Inc. quarterly revenues are $263.8M, which are larger than Revolution Medicines, Inc. quarterly revenues of --. Insmed, Inc.'s net income of -$328.5M is higher than Revolution Medicines, Inc.'s net income of -$364.9M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 52.50x versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.